Medipure’s goal is to conduct pioneering research into the development of cannabinoid-based medicines as prescription pharmaceuticals. The company intends to adopt a unique approach towards these pharmaceuticals, creating propriety cannabinoid derivatives that contain reduced tetrahydrocannabinol (“THC”) content, are not delivered via inhalation, and are both designed and proven to effectively treat specific ailments.